Business Context and Reporting Period
This Form 8-K is a current report filed by Marker Therapeutics, Inc. (MRKR) on August 7, 2025, with the earliest event reported on August 6, 2025. The filing addresses a change in the Company's independent registered public accounting firm.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. However, it notes that the former auditor's reports for the years ended December 31, 2024, and 2023 included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.
Material Changes
- Accountant Resignation: Marcum LLP resigned as the Company's independent registered public accounting firm effective August 6, 2025.
- New Auditor Engagement: CBIZ CPAs P.C. was engaged to serve as the independent registered public accounting firm for the year ending December 31, 2025, effective with the review of the condensed consolidated financial statements for the quarter ended June 30, 2025.
- Reason for Change: The change occurred because CBIZ CPAs acquired the attest business of Marcum LLP effective November 1, 2024.
- No Disagreements: The Company reported no disagreements with Marcum LLP regarding accounting principles, financial statement disclosures, or auditing scope/procedures during the years ended December 31, 2024 and 2023, or through the date of resignation.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the previously disclosed going concern uncertainty. The transition of audit services is administrative in nature, resulting from the acquisition of the former auditor's business.
Investor Verification Checklist
- Verify the status of the "substantial doubt about going concern" noted in prior audit reports and whether the new auditor (CBIZ CPAs) has issued a similar qualification in the Q2 2025 review.
- Confirm the effective date of the new auditor's engagement for the 2025 fiscal year.
- Review the letter from Marcum LLP (Exhibit 16.1) to ensure they concur with the Company's statements regarding the absence of disagreements.
- Monitor upcoming filings (10-Q or 10-K) for updated financial metrics and liquidity positions.